Indications for: Terbinafine Tablets
Onychomycosis of the toenail or fingernail due to tinea unguium.
250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).
Terbinafine Tablets Contraindications:
Chronic or active liver disease.
Terbinafine Tablets Warnings/Precautions:
Onychomycosis: confirm diagnosis with nail specimen. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occur, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Renal impairment (CrCl <50mL/min). Pregnancy (Cat.B), nursing mothers: not recommended.
Terbinafine Tablets Classification:
Terbinafine Tablets Interactions:
Antagonized by rifampin. May be potentiated by cimetidine or CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). May potentiate caffeine or drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May antagonize cyclosporine.
Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; hepatotoxicity, depressive symptoms, smell disturbances.
Formerly known under the brand name Lamisil.